Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell
• Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.
Lineage Cell’s Dry AMD Gene Therapy Demonstrate Functional, Anatomical Improvements
Lineage Cell Therapeutics Inc (NYSE:LCTX) reported updated interim results from its Phase 1/2a study of its lead product candidate, OpRegen cell…
Lineage Cell Therapeutics Reports Updated Interim Results From Ongoing, 24-Patient Phase 1/2a Clinical Study Of Its Lead Product Candidate, OpRegen: 83% Of Cohort 4 Patients’ Treated Eyes Continued To Be At Or Above Baseline
Eighty-Three Percent of All Cohort 4 Patients Continued to Exhibit Stable or Improved BCVA At Least 6 Months Post-Treatment; Visual Acuity Declined in the Majority of Untreated Eyes
Three Patients with Evidence of
Lineage’s Spinal Cord Injury Cell Therapy Return To Clinical Testing
Following feedback received from the FDA, Lineage Cell Therapeutics Inc (NYSE:LCTX) will submit an amendment to its Investigational New Drug…
Lineage Cell Therapeutics To Submit Amendment To IND For OPC1 To Support A Phase 1 Trial To Evaluate Safety And Performance Of Neurgain Technologies Inc.’s Parenchymal Spinal Delivery System
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided an update on the clinical advancement of
Lineage Inks Option Agreement With Amasa Therapeutics For HyStem
Lineage Cell Therapeutics Inc (NYSE:LCTX) has granted an exclusive option to Amasa Therapeutics Inc to acquire an exclusive, royalty-bearing license to…
Earnings Scheduled For May 13, 2021
Companies Reporting Before The Bell
• CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came under pressure following the U.S.